Your support fuels our research to #EndALS! Donate Now
Quick Info
Currently Recruiting
Trial Type
Treatment Type
Drug Trials
None (open label)
Start Date
Contact Information
    Contact information unknown.
Australia, Other
Royal Brisbane and Women's Hospital, Brisbane, QLD 4029, Australia
Contact: Susan Heggie   (07) 3646 3111
Calvary Health Bethlehem Hospital, Melbourne, VIC 3195, Australia
Contact: Emma Windebank   (03) 9596 2853
Macquarie University Hospital, Sydney, NSW 2109, Australia
Contact: Richard Gan
United States, Arizona
Neuromuscular Research Center, Phoenix, AZ, 85028, United States
Contact: Diane Newman   602-410-1675
United States, Colorado
University of Colorado, Aurora, CO, 80045, United States
Contact: Brianna Blume   303-724-3496
National Jewish Health, Denver, CO, 80206, United States
Contact: Jami Hennriksen   303-398-1233
United States, Florida
Lakes Research, Miami Lakes, FL, 33014, United States
Contact: Priscila Valdiviezo   786-362-5763
University of South Florida, Tampa, FL, 33620, United States
Contact: Jessica Shaw   813-844-8061
United States, Illinois
Northwestern University, Chicago, IL, 60611, United States
Contact: Emma Schmidt   312-503-0671
United States, Kentucky
University of Kentucky, Lexington, KY, 40506, United States
Contact: Debby Taylor   617-671-9597
United States, Missouri
Cox Medical Center, Springfield, MO, 65807, United States
Contact: Jessica Ratcliff   417-885-3888
United States, New York
Hospital for Special Surgery, New York, NY, 10021, United States
Contact: Shara Holzberg   646-797-8917
Enrollment Criteria
Breathing Ability
Percent lung function (FVC) or (SVC)
>50% (SVC)
Months Since Onset
Number of months since first symptoms of ALS.
<48 Months
Non-Invasive Ventilation (NIV)
Can PALS use a BiPAP in the trial?
Diaphragm Pacer (DPS)
Can PALS use a DPS in the trial?
Edaravone Usage
Can a PALS use edaravone (Radicut/Radicava) while enrolled in the trial?
Open Label
Update Notes
Sites added
Sites added

Other Information

A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)
Inclusion Criteria:
1. Between 18 and 75 years of age (inclusive) at Screening 1.
2. A diagnosis at Screening 1 and Screening 2 of possible, probable laboratory-supported, probable, or definite ALS, as defined by El Escorial Revised ALS diagnostic criteria.
3. Average decrease in ALSFRS-R of 0.5 to 1.5 (inclusive) points per 4 weeks [use the change between the Screening 1 ALSFRS-R and the most recent ALSFRS-R measure that is at least 12 weeks prior to Screening 1. If no prior values are available, the rate of decline can be estimated as follows: (48-value at screening)/[estimated number of months between screening and ALS symptom onset (weakness and/or dysarthria, and/or dysphagia)].
4. SVC > 50% of predicted value for gender, height, and age at Screening 1.
5. ALS symptom onset (weakness and/or dysarthria, and/or dysphagia) within 48 months of Screening 1.
6. Either no ALS treatment for 4 weeks prior to Screening 1, or stable dosing of riluzole (4 weeks on same dose) and/or at least 2 cycles of edaravone prior to Screening 1; and no change in treatment with either drug between Screening 1 and Screening 2.
7. Women of childbearing potential (WCBP) must agree to abstain from sex or use an adequate method of contraception for the duration of the screening period, the study drug treatment period, and for 28 days after the last dose of study drug.
8. Males must agree to abstain from sex with WCBP or use an adequate method of contraception for the duration of the study drug treatment period and for 75 days after.
9. Capable of providing informed consent and following trial procedures (where subject consents but is unable to sign the informed consent a legally authorized representative (LAR)/surrogate must sign on their behalf).
Exclusion Criteria:
1. ALSFRS-R < 24 at Screening 1.
2. Expected change in dosing of riluzole and/or edaravone between Screening 1 and the end of the study.
3. Presence of other causes of neuromuscular weakness or other neurodegenerative diseases that could interfere with the objectives of the study or the safety of the subject, in the opinion of the Investigator.
4. Mechanical ventilation via tracheostomy. (Use of non-invasive ventilation e.g., continuous positive airway pressure, non-invasive bi-level positive airway pressure or non-invasive volume ventilation is not an exclusion).
5. Any severe comorbidity (including cardiovascular, hematologic, renal, hepatic, or psychiatric diseases) that in the opinion of the Investigator would disallow safe participation in the trial.
6. Suicidal ideation per the Columbia-Suicide Severity Rating Scale (C-SSRS) that in the opinion of the Investigator would pose a safety risk.
7. ALT ≥ 3 x upper limit of normal (ULN) or aspartate aminotransferase (AST) ≥ 3 x ULN at Screening 2.
8. Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73m2 at Screening 2.
9. Participants who, in the opinion of the Investigator, are unable or unlikely to comply with the dosing schedule or study evaluations.
10. Treatment with another investigational drug within 28 days or 5 half-lives of drug before start of study drug, whichever is longer.
11. Treatment with phenylbutyrate and tauroursodeoxycholic acid.
12. On more than one of the following drug classes: long-acting nitrates, beta-blockers, or calcium channel blockers. (Note: subjects may be on one of the drug classes.) 13. Systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 60 mmHg at Screening 2. (Note: in the case of a systolic blood pressure < 90 and/or diastolic blood pressure < 60, BP measurements should be repeated after 10 minutes, and the higher reading used for Inclusion/Exclusion.) 14. Known hypersensitivity to the active (fasudil) or inactive ingredients in the study drug.
15. Known to be pregnant or lactating; or positive pregnancy test for WCBP.
16. At Screening 2, neutrophil count < 1,500/mm3, platelets < 100,000/mm3, international normalized ratio (INR) > 1.5 or any contraindication to or unable to tolerate lumbar puncture, including use of anticoagulant medications such as warfarin. Daily administration of aspirin up to 81 mg is not a contraindication, as long as the dose is held 3 days before lumbar puncture.
The study population will consist of subjects with possible, probable laboratory-supported, probable, or definite ALS, as defined by El Escorial Revised ALS diagnostic criteria, who have ALSFRS-R declining by an average of 0.5-1.5 points per 4 weeks at the time of Screening 1/Visit 1. After consent, participants will undergo two screening evaluations, which will occur over the course of the 8 weeks prior to dosing with study drug. At Screening 1/Visit 1 (8 weeks before start of dosing), ALS assessments of ALSFRS-R/SVC/HHD will be performed, as will safety assessments. Subjects who meet the pertinent inclusion/exclusion criteria will return for a second screening visit (Screening 2/Visit 2) approximately 4 weeks later, and ALS and safety assessment will again be conducted. Subjects who meet the pertinent Screening 2 study entry criteria will be enrolled into the study. On Visit 3, evaluations will be performed and dosing with study drug will begin. Dosing will be initiated at 180 mg/day; after at least 10 subjects have been enrolled and safely treated at 180 mg/day for 4 weeks, subsequent subjects may be enrolled at 240 mg/day. Study drug will be taken for 24 weeks. Participants will have an in-person or telephone visit at Week 1 (Visit 4) to assess for safety and drug compliance. Additional follow-up visits will occur at Weeks 4 (Visit 5), 8 (Visit 6), 12 (Visit 7), 18 (Visit 8) and 24 (Visit 9), during which ALS assessments of ALSFRS-R/SVC/HHD will be performed. A final visit (Visit 10) will be conducted at Week 25 for post-treatment follow-up evaluations. Plasma biomarker collection will occur between enrollment and commencement of treatment, and at Week 12 (Visit 7) and Week 24 (Visit 9). CSF biomarker collection will occur between enrollment and commencement of treatment, and at Week 24 (Visit 9). Laboratory safety assessments and adverse events will be collected at each study visit. Subjects/caregivers will will be asked to maintain a log of study drug compliance, which will be reviewed at each visit.
  • Woolsey Pharmaceuticals
Trial Protocol as Published on
NCT05218668 (First Published: 11/23/2021)